mRNA expression of variant fas molecules in acute leukemia cells

✍ Scribed by Inaba, Hiroto; Komada, Yoshihiro; Li, Qing-Sheng; Zhang, Xao-Li; Tanaka, Shigeki; Azuma, Eiichi; Yamamoto, Hatsumi; Sakurai, Minoru

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 326 KB
• Volume: 62
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/(sici)1096-8652(199911)62:3<150::aid-ajh4>3.0.co;2-y

✦ Synopsis

Fas (Apo-1/CD95

) is a cell membrane receptor involved in apoptotic cell death. Soluble variant forms (sFas) lacking the transmembrane domain due to alternative splicing have been identified. Up-regulation of sFas expression is reportedly implicated in prereceptorial blockage of Fas-induced apoptosis in a dose-dependent manner. We examined mRNA expression of Fas and sFas in fresh leukemia cells. All leukemia cells expressed both mRNAs of full-length Fas (FasFull) and sFas with deletion of exon6 (FasDel6). The ratio of FasFull/FasDel6 mRNA expression was not always correlated with Fas-mediated growth inhibition. Interestingly, in a 6-year-old boy with acute myelogenous leukemia, blast cells obtained at onset and at the time of bone marrow relapses expressed distinct amounts of FasDel6 mRNA. Furthermore, the level of FasDel6 expression appeared to be correlated with Fas-resistance in leukemia blasts. In addition, sFas protein levels were elevated in patients' sera at onset with subsequent return to normal levels after complete remission. These results indicated that sFas could be synthesized and released by leukemia blasts and suggested that up-regulation of Fas variant transcript might render leukemia blasts resistant to Fas-mediated growth inhibition in certain cases. Am. J. Hematol. 62:150-158, 1999.